{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:06:29Z","timestamp":1778807189534,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> We investigated the prevalence, demographic and clinical features, and risk factors associated with drug-induced liver injury (DILI) during the treatment of brucellosis inpatients in a retrospective study.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We collected the clinical data of 782 brucellosis inpatients admitted at the Shawan County People\u2019s Hospital, Xinjiang, from 2015\u20132019. All cases were re-evaluated using the international consensus of DILI criteria and RUCAM rating scale. 71 patients were confirmed as DILI cases and compared with 523 other patients with normal liver function.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> It was indicated that DILI occurred with a prevalence of about 9.08% among brucellosis inpatients receiving drug therapy. Hepatocellular injury was the most common type of DILI (61.97%, 95% confidence interval [CI] 50.34\u201372.37), followed by mixed (23.94%, 95% CI 15.52\u201335.04) and cholestatic types (14.08%, 95% CI 7.83\u201324.02). In addition, 13.64% of the hepatocellular DILI cases fulfilled Hy\u2019s law criteria and only two cases (2.82%) progressed to severe DILI. Most patients adopted the combination of rifampicin, antipyretic analgesics, anti-infective agents, and traditional Chinese medicine for the treatment of brucellosis, with all the 71 patients taking rifampicin as the drug of choice. Multivariable logistic regression analyses indicated that obesity, regular alcohol intake, and decreased serum albumin were the independent risk factors of DILI in patients with brucellosis after adjusting for gender, age, and ethnicity.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> DILI occurred in a minority of inpatients diagnosed with brucellosis receiving rifampicin-based therapeutic regimen. In addition, obesity, alcohol abuse, and decreased serum albumin were valuable predictors of the risk of DILI in patients with brucellosis.<\/jats:p>","DOI":"10.3389\/fphar.2021.657805","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T08:43:21Z","timestamp":1620636201000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The Characteristics, Prevalence, and Risk Factors of Drug-Induced Liver Injury Among Brucellosis Inpatients in Xinjiang, China"],"prefix":"10.3389","volume":"12","author":[{"given":"Maermaer","family":"Tuohutaerbieke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhize","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamixi","family":"Mamuerjiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/00002018-200730040-00001","article-title":"Drug-induced Liver Injury","volume":"30","author":"Abboud","year":"2007","journal-title":"Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case Definition and Phenotype Standardization in Drug-Induced Liver Injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1586\/14787210.6.1.109","article-title":"Therapeutic Options for Human Brucellosis","volume":"6","author":"Al-Tawfiq","year":"2008","journal-title":"Expert Rev. Anti-infective Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.micpath.2019.02.011","article-title":"Clinical and Serological Approach to Patients with Brucellosis: A Common Diagnostic Dilemma and a Worldwide Perspective","volume":"129","author":"Avijgan","year":"2019","journal-title":"Microb. Pathogenesis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, Presentation, and Outcomes in Patients with Drug-Induced Liver Injury in the General Population of Iceland","volume":"144","author":"Bj\u00f6rnsson","year":"2013","journal-title":"Gastroenterology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of Obesity on Drug Metabolism and Elimination in Adults and Children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/j.ijid.2009.06.031","article-title":"Clinical Manifestations and Complications in 1028 Cases of Brucellosis: a Retrospective Evaluation and Review of the Literature","volume":"14","author":"Buzgan","year":"2010","journal-title":"Int. J. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.285.20.2572","article-title":"Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection--New York and Georgia, 2000","volume":"285","year":"","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1001\/jama.286.12.1445","article-title":"Update: Fatal and Severe Liver Injuries Associated with Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society\/CDC recommendations--United States, 2001","volume":"286","year":"","journal-title":"JAMA"},{"key":"B10","volume-title":"Brucellosis Reference Guide: Exposures, Testing, and Prevention","year":"2017"},{"key":"B11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","article-title":"Drug-induced Liver Injury: Interactions between Drug Properties and Host Factors","volume":"63","author":"Chen","year":"2015","journal-title":"J. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3760\/cma.j.issn.0254-6450.2016.07.005","article-title":"A Study on the Occurrence and Outcome of Drug-Induced Hepatitis in Hospitalized Patients Receiving Anti-tuberculosis Treatment","volume":"37","author":"Chen","year":"2016","journal-title":"Chin. J. Epidemiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cgh.2017.12.036","article-title":"Heavy Consumption of Alcohol Is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-Induced Liver Injury Compared to Non-Drinkers","volume":"16","author":"Dakhoul","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B14","first-page":"167","article-title":"Antituberculous Drug-Induced Liver Injury: Current Perspective","volume":"32","author":"Devarbhavi","year":"2011","journal-title":"Trop. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","year":"2019","journal-title":"J. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1128\/AAC.50.1.22-33.2006","article-title":"Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies","volume":"50","author":"Falagas","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"B17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF00560341","article-title":"Clinical Toxicity of Chloridazepoxide and Diazepam in Relation to Serum Albumin Concentration: A Report from the Boston Collaborative Drug Surveillance Program","volume":"7","author":"Greenblatt","year":"1974","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40249-020-00673-8","article-title":"Brucellosis in China: History, Progress and Challenge","volume":"9","author":"Jiang","year":"2020","journal-title":"Infect. Dis. Poverty"},{"key":"B19","first-page":"323","article-title":"Brucellosis Diagnosis and Treatment Guide (Trial)","volume":"25","year":"2012","journal-title":"Infect. Dis. Inf. (Chinese)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related Hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B21","first-page":"1285","article-title":"Clinical Treatment of Anti-tuberculosis Treatment Induced Liver Injury in Patients with Drug-Resistant Tuberculosis","volume":"29","author":"Nie","year":"2017","journal-title":"Med. J. West China"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s10096-014-2064-4","article-title":"Liver Involvement in Patients with Brucellosis: Results of the Marmara Study","volume":"33","author":"Ozturk-Engin","year":"2014","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMra050570","article-title":"Brucellosis","volume":"352","author":"Pappas","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1473-3099(06)70382-6","article-title":"The New Global Map of Human Brucellosis","volume":"6","author":"Pappas","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1086\/501359","article-title":"Efficacy of Gentamicin Plus Doxycycline versus Streptomycin Plus Doxycycline in the Treatment of Brucellosis in Humans","volume":"42","author":"Roushan","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and Etiology of Drug-Induced Liver Injury in Mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/bmj.39497.500903.25","article-title":"Treatment of Human Brucellosis: Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"336","author":"Skalsky","year":"2008","journal-title":"Bmj"},{"key":"B29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00003495-199753020-00005","article-title":"Recognition and Optimum Treatment of Brucellosis","volume":"53","author":"Solera","year":"1997","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol. Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.657805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T08:43:33Z","timestamp":1620636213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.657805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":30,"alternative-id":["10.3389\/fphar.2021.657805"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.657805","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"article-number":"657805"}}